This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neoplasm of uncertain or unknown behaviour of meninges뇌수막의 행동양식 불명 또는 미상의 신생물

Contents and key points
ItemDetails
A. Classification codesICD-10: D42 (Neoplasm of uncertain or unknown behavior of meninges) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date)
B. SynonymsMeningioma, atypical meningioma (WHO grade 2), spinal meningioma, meningeal neoplasm of uncertain behavior; D42.0 cerebral meninges, D42.1 spinal meninges, D42.9 unspecified
C. Adult onsetPresents mainly in adults in their 40s~70s and is more common in women. Incidental detection on imaging is increasing.
1. HistoryMeningioma was first described by Felix Plater in 1614 and named meningioma by Harvey Cushing in 1922, and the 2021 WHO classification introduced a molecularly based reclassification.
2. CausesCranial irradiation is the most definite environmental risk factor, and exposure to female hormones and NF2 syndrome are important risk factors.
3. GeneticsNF2 gene mutation (chromosome 22 loss, about 50~60%) is the most common, and TRAF7, KLF4, AKT1, and SMO mutations are characteristic of skull base tumors.
4. General epidemiologyMeningioma is the most common primary intracranial tumor, accounting for about 36~37%, with an annual incidence of about 8~10 per 100,000 population.
5. PathophysiologyLoss of NF2 gene function leads to merlin protein deficiency, which aberrantly activates the Hippo, FAK, and PI3K pathways, causing neoplastic transformation of meningothelial cells.
6. SymptomsHeadache, seizures, focal neurologic deficits (visual disturbance, hemiparesis, etc.), and cognitive changes are the main symptoms, and about 40% are asymptomatic.
7. SignsOptic disc edema, signs of focal neurologic deficit, papilledema (with increased intracranial pressure), and signs of spinal cord compression in spinal meningeal tumors are observed.
8. ScreeningRegular brain MRI recommended in patients with NF2 syndrome; there is no general population screening, but prompt imaging evaluation is important when neurologic symptoms occur.
9. DiagnosisMRI (contrast-enhanced T1, FLAIR, DWI) is central; tissue confirmation, molecular pathology (methylation classification, TERT mutation, etc.), and PET-CT are used as adjuncts.
10. TreatmentObservation, surgical resection (Simpson grade), and radiation therapy (SRS/FSRT) are the 3 main treatment strategies, individualized by grade and location.
11. PrognosisWHO grade 1: 10-year recurrence rate about 25%; grade 2: 5-year recurrence rate 40~50%; grade 3 (anaplastic meningioma): poor, with a 5-year survival rate of about 30~50%.
12. PreventionMinimizing cranial irradiation in children, regular follow-up of NF2 patients, no concern related to non-ionizing radiation such as smartphones (current evidence).
13. ReferencesIntracranial meningiomas: an update of the 2021 WHO classifications and review of management … and 9 other papers

1. History

The history of the description of meningioma begins in 1614 when the Swiss physician Felix Plater first reported a tumor originating from the meninges. In 1743, Antonio Pacchioni described the arachnoid granulations, which were later recognized as the cells of origin of meningioma. In the 19th century, surgical approaches to meningioma were attempted but were limited by high mortality. In 1888, William Macewen succeeded in the first surgical removal of a meningioma, and subsequent advances in neurosurgical techniques greatly transformed the field.

The term meningioma was coined by Harvey Cushing in 1922. Cushing unified a group of tumors then called by various names such as "dural endothelioma", "psammoma", and "endothelioma" as tumors of meningeal origin and named them meningioma. In 1938, a forerunner of the "Simpson grading" based on surgical outcomes and recurrence rates was proposed, and in 1957 Donald Simpson published a classification systematizing the relationship between the extent of surgical resection and recurrence. The system from Simpson grade I (complete resection + resection of dura and bone) to grade 5 (simple decompression) is still used today as the standard for surgical approaches.

The WHO classification of brain tumors was revised in 1979, 1993, 2000, 2007, 2016, and 2021, and the grading criteria for meningioma have been continuously refined. In the 2021 WHO classification of CNS tumors (5th edition), molecular markers were fully integrated into meningioma classification for the first time. TERT promoter mutation and CDKN2A/B homozygous deletion are used to determine WHO grade, introducing a system in which a tumor is upgraded to grade 3 if these alterations are present even when it is histologically grade 1. It was also suggested that DNA methylation profiling can be used to classify meningiomas into biological groups.


2. Causes

The development of meningioma is understood as the combined action of environmental factors and genetic predisposition. Cranial irradiation is the most definitely confirmed environmental risk factor to date. In patients who received whole-brain radiation in childhood for treatment of leukemia or medulloblastoma, the risk of meningioma increases tens of times, and a linear dose-response relationship between radiation dose and meningioma risk has been confirmed. Radiation-induced meningiomas arise after a latency period of 15~30 years after irradiation and tend to be multiple and of more aggressive histologic types.

Female sex hormones have been studied as a risk factor underlying the marked female predominance of meningioma (F:M about 2:1). Progesterone receptors (about 70%) and estrogen receptors (about 30%) are expressed in meningioma cells, and cases of accelerated meningioma growth during pregnancy have been reported. Study results are mixed on whether oral contraceptives and hormone replacement therapy (HRT) increase meningioma risk, but a recent large cohort study (the French KHANA study) confirmed that long-term use of high-dose progestin (cyproterone acetate hydrochloride) increases the risk of meningioma more than 10-fold, leading regulatory authorities to change their recommendations.

Neurofibromatosis type 2 (NF2) is the most important genetic risk factor for meningioma; meningioma develops in about 50~60% of NF2 patients. NF2-associated meningiomas are multiple, occur at a younger age, and are more likely to be of higher grade. An association between head trauma and meningioma has been raised in some case reports, but consistent evidence has not been obtained in large cohort studies. An association between mobile phone use (non-ionizing radiation) and meningioma has not been confirmed to date in extensive epidemiologic studies (INTERPHONE, Epidemiology of Brain Tumors).


3. Genetics

The most characteristic genetic abnormality of meningioma is chromosome 22 loss and NF2 gene (22q12) mutation. The NF2 gene encodes a tumor suppressor protein called merlin (or schwannomin), and this mutation is found at a high frequency of about 50~60% in cerebral convexity meningiomas. Merlin functions as a tumor suppressor protein that inhibits cell growth through the Hippo signaling pathway, FAK (focal adhesion kinase), the PI3K/AKT pathway, and others, and its loss causes simultaneous activation of multiple cell survival pathways.

In meningiomas located at the skull base, NF2 mutations are rare, and instead TRAF7, KLF4, AKT1, and SMO mutations are characteristically found. TRAF7 mutations are found in about 25% of skull base meningiomas, often together with KLF4 mutations, and are associated with specific locations and histologic types of meningioma (secretory meningioma). The AKT1 E17K mutation is found mainly in skull base (sphenoid ridge) meningiomas. SMO mutations are characteristically observed in meningiomas located at the olfactory groove.

As molecular criteria newly introduced in the 2021 WHO classification, TERT promoter mutation (C228T or C250T) and CDKN2A/B homozygous deletion are used to designate WHO grade 3 (anaplastic meningioma). These alterations function as molecular markers predicting an aggressive clinical course even in tumors that appear histologically lower grade. DNA methylation profiling classifies meningiomas into at least 6 methylation classes, and studies are being published showing that it predicts clinical course more accurately than histologic grade. POLR2A mutations and BAP1 mutations are also reported in high-grade meningiomas.


4. General epidemiology

Meningioma is the most common primary central nervous system tumor, accounting for about 36~37% of intracranial tumors. According to the Central Brain Tumor Registry of the United States (CBTRUS), the annual incidence is about 8~10 per 100,000 population, about 3 times that of glioblastoma (about 3.2 per 100,000). In Korea Central Cancer Registry data, the annual number of new intracranial meningioma cases is estimated at about 3,000~4,000, and the incidence is increasing. This increase partly reflects more incidental detection due to the spread of MRI.

It is about 2~3 times more common in women than in men, and the median age at onset is about 65. Meningioma can occur at any age but is rare in children (about 2% of all pediatric brain tumors), and pediatric meningiomas tend to be more aggressive than adult ones. By location, about 40~50% of intracranial meningiomas are at the cerebral convexity (including parasagittal), about 15~20% at the skull base (sphenoid wing, cavernous sinus, cerebellopontine angle), and about 5~10% in the posterior fossa. Spinal meningioma (D42.1) accounts for about 25~45% of all spinal tumors, occurs overwhelmingly in women (about 80%), and most often arises in the thoracic spinal meninges.


5. Pathophysiology

The most central molecular event in the pathogenesis of meningioma is loss of NF2/merlin function. Merlin is a cytoskeletal linker protein with a FERM domain of the ERM (Ezrin-Radixin-Moesin) protein family that regulates the binding between cell surface adhesion molecules (E-cadherin, CD44) and intracellular signaling proteins. Depending on its phosphorylation state, merlin switches between active (hypophosphorylated) and inactive (hyperphosphorylated) forms, and when merlin is lost due to NF2 mutation, the key upstream regulatory function of the Hippo signaling pathway (LATS1/2 → YAP/TAZ) is lost. As a result, YAP/TAZ translocates to the nucleus and binds to TEAD transcription factors, increasing expression of cell proliferation and survival genes (CTGF, CYR61, etc.).

In NF2-independent meningiomas, SMO (smoothened receptor of the sonic hedgehog signaling pathway) mutations constitutively activate hedgehog signaling, and the AKT1 E17K mutation persistently activates the PI3K/AKT/mTOR pathway, promoting cell growth. In the development of skull base meningiomas, these pathways combine with specialized anatomic meningeal cell subtypes of the skull base to produce location-specific oncogenic features. Progression to WHO grade 2 (atypical meningioma) involves the accumulation of additional genetic abnormalities (TERT promoter mutation, CDKN2A/B loss, KDM6A loss, SMARCB1/SMARCA4 mutations). In radiation-induced meningiomas, non-homologous recombination due to DNA double-strand breaks and misrepair accelerates chromosomal rearrangements and accumulation of genetic abnormalities.


6. Symptoms

The symptoms of meningioma vary greatly with tumor location, size, growth rate, and relationship to surrounding brain structures. About 40% of meningiomas are asymptomatic tumors found incidentally on CT or MRI performed for head trauma or other reasons. Because meningiomas grow slowly, the brain gradually adapts, and symptom onset is often delayed.

When symptoms are present, the most common is headache. Headache is usually intermittent and nonspecific at first but becomes more severe and persistent as the tumor grows. Headache due to increased intracranial pressure is worse in the morning and accompanied by nausea and vomiting. Seizures are common with meningiomas adjacent to the surface of the cerebral hemispheres (especially near the motor cortex or supplementary motor area), and a first seizure may be the first symptom of meningioma. Focal neurologic deficits vary greatly by location. Sphenoid wing meningiomas cause decreased vision, visual field defects, and proptosis, and cavernous sinus meningiomas cause diplopia (palsies of cranial nerves III, IV, and VI). Olfactory groove meningiomas cause anosmia, frontal lobe dysfunction, and personality change. Cerebellopontine angle meningiomas cause hearing loss, facial sensory disturbance, and cerebellar ataxia. Spinal meningiomas cause lower limb paralysis below the level of compression, sensory disturbance, and bladder and bowel dysfunction.


7. Signs

The signs found on neurologic examination vary with location and grade. Papilledema is a sign of increased intracranial pressure found on funduscopy and appears when a meningioma is large or blocks cerebrospinal fluid circulation. Focal neurologic deficits are caused by compression or invasion depending on tumor location. Tumors adjacent to the motor cortex cause hemiparesis or unilateral upper limb monoparesis, and tumors adjacent to the frontal lobe cause Broca aphasia and executive dysfunction. Tumors adjacent to the parietal lobe cause hemispatial neglect and sensory deficits, and those adjacent to the occipital lobe cause visual field defects. Tumors adjacent to the cerebellum cause ataxia, gait disturbance, and incoordination.

With optic nerve compression, abnormal pupil size, loss of the light reflex, and constriction of the visual field on vision testing are found. In sphenoid wing meningiomas, proptosis and eyelid edema may be observed. Signs of cranial nerve dysfunction appear as facial pain and hypoesthesia (trigeminal nerve), facial asymmetry and palsy (facial nerve), and hearing loss and tinnitus (acoustic nerve). In spinal meningiomas, spastic paraparesis below the level of the lesion, a positive Babinski sign, decreased or absent anal reflex, and bladder dysfunction are found.


8. Screening

Systematic screening of the general population for meningioma is not currently recommended. However, regular surveillance of high-risk populations is important. In patients with NF2 syndrome and carriers of confirmed pathogenic NF2 gene variants, brain and spinal MRI should be performed regularly to monitor early for the development of meningioma along with neurofibromas and vestibular schwannomas (bilateral vestibular schwannoma). In NF2 patients, the follow-up interval for central nervous system tumors including meningioma is generally once every 1~3 years, with immediate evaluation when symptoms change.

For users of high-dose progestin preparations (especially long-term users of cyproterone acetate), baseline MRI before starting and regular MRI follow-up during use are recommended, and the French health authority (ANSM) has published specific guidance on this. In survivors who received cranial irradiation in childhood, long-term follow-up brain MRI is useful for early detection of secondary meningioma. When new neurologic symptoms develop after head trauma, early brain MRI or CT is important.


9. Diagnosis

In the diagnosis of meningioma, MRI (magnetic resonance imaging) is the most important imaging test. On gadolinium-enhanced MRI, meningiomas show strong, homogeneous enhancement, and the "dural tail sign", a typical dura-based pattern, is characteristic. They are isointense or hypointense to brain on T1-weighted images and show variable signal intensity on T2-weighted images. Fibrous meningiomas tend to be hypointense on T2 and secretory meningiomas hyperintense on T2, which helps predict histologic type. On diffusion-weighted imaging (DWI), high-grade meningiomas show restricted water diffusion (low ADC). MR spectroscopy, MR perfusion, and fMRI are used as adjuncts.

CT is especially useful for evaluating calcification (observed in about 20~30% of meningiomas) and adjacent bone reaction (hyperostosis or bone erosion). In skull base meningiomas, CT is essential for determining the extent of bone involvement before surgery. Tissue confirmation is made by pathologic examination of the surgical resection specimen, and mitotic count (/10HPF or /2mm²), presence of necrosis, brain invasion, nuclear atypia, and so on are the criteria for determining WHO grade. On immunohistochemistry, EMA (epithelial membrane antigen), vimentin, and somatostatin receptor 2 (SSTR2) are used to diagnose meningioma. Recently, DNA methylation profiling has been introduced as a tool complementing histologic grade in molecular subtyping and prognostic prediction of meningioma.


10. Treatment

Treatment of meningioma is individualized according to tumor size, location, WHO grade, growth rate, presence of symptoms, and the patient's general condition. The three main treatment strategies are observation, surgical resection, and radiation therapy.

Observation (wait-and-see) is considered for small, incidentally found, asymptomatic meningiomas (3cm or less in diameter). Growth is monitored with MRI first after 6 months and then at 1~2-year intervals. In elderly patients or those at high surgical risk, small tumors often remain stable without growth for a long time, so observation is reasonable.

Surgical resection is the first-line treatment for symptomatic or growing meningiomas. Complete resection (Simpson grade 1~2) is most effective in preventing recurrence, and when possible the dural attachment and adjacent bone are also removed. In skull base meningiomas or meningiomas near the venous sinuses, complete resection is often impossible because of the risk of injury to vascular and neural structures. Endoscopic assistance, fluorescence guidance (5-ALA), neuronavigation, and neurophysiologic monitoring increase surgical safety. As radiation therapy, Gamma Knife (Gamma Knife SRS), CyberKnife, proton therapy, and fractionated stereotactic radiotherapy (FSRT) are used. SRS is effective, with tumor control rates of 90~95% in small (3cm or less) inoperable or recurrent meningiomas. In WHO grades 2~3, radiation therapy after resection contributes to reducing the recurrence rate. No drug therapy has currently been established as standard, and hydroxyurea, SMO inhibitors (vismodegib), and immune checkpoint inhibitors are in clinical trials.


11. Prognosis

The prognosis of meningioma is determined by WHO grade and extent of resection. WHO grade 1 meningioma has a favorable prognosis, with a 10-year recurrence rate of about 10~25% after complete resection. With incomplete resection, the 5-year recurrence rate rises to about 40%. The overall 5-year survival rate is over 95% for WHO grade 1. WHO grade 2 (atypical meningioma) follows a more aggressive course, with a 5-year recurrence rate of about 40~50% even after complete resection, and the 10-year recurrence rate reaches 60~80%. Adding radiation therapy after resection significantly reduces the recurrence rate.

WHO grade 3 (anaplastic meningioma) has the poorest prognosis, with a median survival of about 2~3 years and a 5-year survival rate of about 30~50%. Spinal meningiomas are relatively easier to resect completely than intracranial meningiomas, so the recurrence rate is low and the prognosis is often favorable. Meningiomas with TERT promoter mutation follow a more aggressive course regardless of histologic grade, and this is used as a molecular prognostic factor. The higher the Ki-67 proliferation index, and the closer the location to the cavernous sinus or optic chiasm, the poorer the prognosis.


12. Prevention

Prevention of meningioma is directed at minimizing known risk factors. The most important primary prevention is minimizing cranial irradiation in children. Currently, advances in proton therapy and radiation therapy techniques in treating pediatric brain tumors are greatly reducing radiation exposure of normal meningeal tissue. Nevertheless, survivors who received radiation therapy for pediatric brain tumors, head and neck cancer, or leukemia need awareness of the risk of secondary meningioma and regular follow-up.

Avoiding long-term use of high-dose progestin-class drugs (cyproterone acetate, chlormadinone acetate, etc.) may contribute to preventing meningioma. In patients already using these drugs, it is important to discuss switching to alternative drugs with their physician, along with regular MRI follow-up. In patients with NF2 syndrome, detecting meningiomas at a small stage through early genetic diagnosis and regular follow-up increases the likelihood of treatment with less risky surgery or radiation therapy. To date, there is no strong evidence for a relationship between diet, lifestyle (exercise, weight), viral infection, and the like and the risk of meningioma.


13. References

  1. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23(Suppl 2):iii1-iii105. DOI: 10.1093/neuonc/noab200. PMID: 34608945.

  2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. DOI: 10.1093/neuonc/noab106. PMID: 34185076.

  3. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821-1834. DOI: 10.1093/neuonc/noab150. PMID: 34181734.

  4. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. 1988;318(11):684-688. DOI: 10.1056/NEJM198803171810. PMID: 3125436.

  5. Bi WL, Abedalthagafi M, Horowitz P, et al. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016;125(3):525-535. DOI: 10.3171/2015.6.JNS15591. PMID: 26684776.

  6. Sahm F, Schrimpf D, Olar A, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5):djv377. DOI: 10.1093/jnci/djv377. PMID: 26668184.

  7. Sade B, Chahlavi A, Krishnaney A, et al. World Health Organization Grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery. 2007;61(6):1194-1198. DOI: 10.1227/01.neu.0000306108.34338.d4. PMID: 18162903.

  8. Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol. 2009;4:42. DOI: 10.1186/1748-717X-4-42. PMID: 19740431.

  9. Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57(6):1088-1095. DOI: 10.1227/01.NEU.0000186728.45716.87. PMID: 16331155.

  10. Islim AI, Mohan M, Moon RDC, et al. Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J Neurooncol. 2019;142(2):211-221. DOI: 10.1007/s11060-019-03104-3. PMID: 30806905.